AGP Picks
View all

Idefirix market gains on kidney transplant demand

Nov. 4, 2026
Idefirix market gains on kidney transplant demand
By AI, Created 14:00 UTC, Nov 04, 2026, AGP -

The Business Research Company says the Idefirix market is expanding as kidney transplant demand rises and more patients need help overcoming donor-specific antibodies. Europe held the largest share in 2025, and the report points to faster growth ahead as transplant volumes, specialized clinics and precision immunology adoption increase.

Why it matters: - Idefirix targets a hard problem in kidney transplantation: highly sensitized patients who face donor compatibility barriers and rejection risk. - The market’s growth ties directly to rising kidney disease burden, transplant demand and the need for more effective desensitization options. - The report frames Idefirix as part of a broader shift toward precision immunology in transplant care.

What happened: - The Business Research Company released an Idefirix market analysis report on November 4, 2026. - The report says the Idefirix market is gaining momentum as kidney transplantation technology addresses donor shortages and immune compatibility challenges. - The company offers a free sample of the Idefirix market report and a full report.

The details: - Idefirix, also known as imlifidase, is an enzyme-based therapy designed to reduce donor-specific antibodies in highly sensitized kidney transplant recipients. - The therapy cleaves IgG antibodies to help desensitize patients before transplantation. - The report says this improves compatibility with donor organs for patients who might otherwise be rejected because of antibody incompatibility. - Historical market growth has been driven by kidney shortages, donor-specific antibodies, limits of conventional desensitization methods and early clinical successes for imlifidase. - Expansion in transplant centers also supported demand. - The forecast period points to more growth from rising kidney transplant demand, longer waiting lists and broader use of precision immunology approaches. - Supportive regulation and more specialized transplant clinics are also expected to help. - The report highlights growing use of desensitization therapies, more focus on highly sensitized patients, enzyme-based immunomodulation, higher transplant volumes and better access to advanced transplant care. - Rising kidney disease prevalence and incidence worldwide is a major driver of the market. - Kidney disease burden is rising because of aging populations, more diabetes and hypertension, lifestyle factors and genetic predispositions. - A June 2023 Kidney Research report said acute kidney injury cases are expected to rise from about 615,000 in 2022 to 637,000 by 2033. - Europe held the largest share of the Idefirix market in 2025. - Europe is also forecast to grow the fastest over the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report update adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.

Between the lines: - The report suggests Idefirix is moving from a niche transplant tool toward a broader commercial opportunity as transplant systems look for ways to expand eligibility. - Europe’s lead may reflect stronger transplant infrastructure and earlier adoption of advanced desensitization therapies. - The emphasis on highly sensitized patients points to a market built around a clinically difficult, high-need population rather than broad routine use.

What’s next: - Market growth will likely track transplant volumes, waiting list pressure and adoption of advanced immunology tools. - Specialized transplant clinics and broader access to advanced care could widen use over time. - The company invites readers to contact its expert team for more information through the report materials and social channels.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.